Bioventus Reports Q4 2025 Earnings: 10% Organic Growth, Record Cash from Operations, and Strong Guidance for 2026

Bioventus Inc reported Q4 2025 revenue of $158 million, a 3% YoY increase, with 10% organic growth. Adjusted EBITDA reached $37 million, a 30% increase YoY, and cash from operations nearly doubled to $38 million. The company reduced its net leverage ratio below 2.5 times and provided 2026 financial guidance with net sales projected between $600 million and $610 million.